Last reviewed · How we verify
Epilepsy having focal-onset seizures — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Xcopri | CENOBAMATE | Sk Life | Gamma-aminobutyric acid receptor subunit alpha-4 | 2019-01-01 | ||
| Xcopri | Xcopri | SK Life Science, Inc. | Gamma-aminobutyric acid receptor subunit alpha-4, Gamma-aminobutyric acid receptor subunit alpha-6 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- SK Life Science, Inc. · 1 drug in Epilepsy having focal-onset seizures
- Sk Life · 1 drug in Epilepsy having focal-onset seizures
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Epilepsy having focal-onset seizures:
- Epilepsy having focal-onset seizures treatment updates — RSS
- Epilepsy having focal-onset seizures treatment updates — Atom
- Epilepsy having focal-onset seizures treatment updates — JSON
Cite this brief
Drug Landscape (2026). Epilepsy having focal-onset seizures — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/epilepsy-having-focal-onset-seizures. Accessed 2026-06-10.
Related
- Epilepsy having focal-onset seizures full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing